Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
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
U3mDBXMkLS7g0jjN
Listen
